Target type: biologicalprocess
The process in which a pyrimidine-containing compound is transported across a membrane. A pyrimidine-containing compound is any compound that contains pyrimidine or a formal derivative thereof. [GOC:mah]
Pyrimidine-containing compound transmembrane transport is a crucial biological process that enables the movement of pyrimidine bases, such as cytosine, thymine, and uracil, across cell membranes. These bases are essential building blocks for nucleic acids (DNA and RNA), which play vital roles in genetic information storage, transmission, and protein synthesis. The transport process is highly regulated and involves specialized membrane proteins known as pyrimidine transporters. These proteins facilitate the passage of pyrimidines across the cell membrane, ensuring the appropriate levels of these essential molecules within the cell.
The process typically involves the following steps:
1. **Binding of pyrimidine:** Pyrimidine molecules bind to specific sites on the transporter protein, initiating the transport process. The binding event can be influenced by factors such as the concentration gradient of the pyrimidine across the membrane, the pH of the environment, and the presence of other molecules that might compete for binding sites.
2. **Conformational change:** Upon binding, the transporter protein undergoes a conformational change, altering its structure to allow passage of the pyrimidine across the membrane. This change can be triggered by various mechanisms, including phosphorylation, binding of cofactors, or changes in membrane potential.
3. **Translocation of pyrimidine:** The pyrimidine molecule moves across the membrane through a channel or pore created by the transporter protein. This movement is driven by the concentration gradient of the pyrimidine, the electrical potential difference across the membrane, or the energy provided by ATP hydrolysis.
4. **Release of pyrimidine:** Once the pyrimidine molecule reaches the other side of the membrane, it dissociates from the transporter protein, completing the transport cycle.
The process of pyrimidine-containing compound transmembrane transport is essential for maintaining cellular function and is tightly regulated by a variety of mechanisms. Disruptions in this process can lead to various diseases, including cancer and genetic disorders. For instance, mutations in pyrimidine transporter genes can lead to deficiencies in pyrimidine metabolism, causing severe neurological defects.
Furthermore, this process is targeted by certain drugs used in cancer treatment. Some drugs inhibit the activity of pyrimidine transporters, thereby blocking the uptake of pyrimidines into cancer cells, leading to their growth inhibition.
Overall, the complex and tightly regulated process of pyrimidine-containing compound transmembrane transport is essential for maintaining cellular homeostasis and is of great significance in various biological processes, including nucleic acid synthesis and disease development.'
"
Protein | Definition | Taxonomy |
---|---|---|
Solute carrier family 28 member 3 | A solute carrier family 28 member 3 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q9HAS3] | Homo sapiens (human) |
Equilibrative nucleoside transporter 1 | An equilibrative nucleoside transporter 1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q99808] | Homo sapiens (human) |
Equilibrative nucleoside transporter 2 | An equilibrative nucleoside transporter 2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q14542] | Homo sapiens (human) |
Sodium/nucleoside cotransporter 2 | A sodium/nucleoside cotransporter 2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:O43868] | Homo sapiens (human) |
Sodium/nucleoside cotransporter 1 | A sodium/nucleoside cotransporter 1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:O00337] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
dilazep | dilazep : A member of the class of diazepanes that is 1,4-diazepane substituted by 3-[(3,4,5-trimethoxybenzoyl)oxy]propyl groups at positions 1 and 4. It is a potent adenosine uptake inhibitor that exhibits antiplatelet, antianginal and vasodilator properties. Dilazep: Coronary vasodilator with some antiarrhythmic activity. | benzoate ester; diazepane; diester; methoxybenzenes | cardioprotective agent; platelet aggregation inhibitor; vasodilator agent |
dipyridamole | dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots. Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) | piperidines; pyrimidopyrimidine; tertiary amino compound; tetrol | adenosine phosphodiesterase inhibitor; EC 3.5.4.4 (adenosine deaminase) inhibitor; platelet aggregation inhibitor; vasodilator agent |
lidoflazine | Lidoflazine: Coronary vasodilator with some antiarrhythmic action. | diarylmethane | |
phloretin | dihydrochalcones | antineoplastic agent; plant metabolite | |
floxuridine | floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract. Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract. | nucleoside analogue; organofluorine compound; pyrimidine 2'-deoxyribonucleoside | antimetabolite; antineoplastic agent; antiviral drug; radiosensitizing agent |
uridine | uridines | drug metabolite; fundamental metabolite; human metabolite | |
phlorhizin | aryl beta-D-glucoside; dihydrochalcones; monosaccharide derivative | antioxidant; plant metabolite | |
resacetophenone | 2',4'-dihydroxyacetophenone : A dihydroxyacetophenone that is acetophenone carrying hydroxy substituents at positions 2' and 4'. resacetophenone: structure in first source | dihydroxyacetophenone; resorcinols | plant metabolite |
methylthioinosine | Methylthioinosine: 6-(Methylthio)-9-beta-D-ribofuranosylpurine. An analog of inosine with a methylthio group replacing the hydroxyl group in the 6-position. | purine ribonucleoside; thiopurine | |
hyaluronoglucosaminidase | kinetin riboside: preferentially induces apoptosis by modulating Bcl-2 family proteins and caspase-3 in cancer cells; structure in first source | purine nucleoside | |
gemcitabine | gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer. | organofluorine compound; pyrimidine 2'-deoxyribonucleoside | antimetabolite; antineoplastic agent; antiviral drug; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; environmental contaminant; immunosuppressive agent; photosensitizing agent; prodrug; radiosensitizing agent; xenobiotic |
draflazine | draflazine: a nucleoside transport inhibitor; has cardioprotective effect; draflazine is the (-)-enantiomer; R 88016 is the (+)-enantiomer | ||
adenosine | quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit | adenosines; purines D-ribonucleoside | analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent |
4-nitrobenzylthioinosine | 4-nitrobenzylthioinosine: inhibitor of nucleoside transport; acts on ENT1 | purine nucleoside | |
2,4,6-trihydroxyacetophenone | 2',4',6'-trihydroxyacetophenone : A benzenetriol that is acetophenone in which the hydrogens at positions 2, 4, and 6 on the phenyl group are replaced by hydroxy groups. It is used as a matrix in matrix-assisted laser desorption/ionization (MALDI) mass spectrometry for the analysis of acidic glycans and glycopeptides. monoacetylphloroglucinol: structure in first source | aromatic ketone; benzenetriol; methyl ketone | MALDI matrix material; plant metabolite |
2,6-dihydroxyacetophenone | 2,6-dihydroxyacetophenone: inhibits aminopyrine-N-demethylase in rat liver microsomal preparations | aromatic ketone | |
n(6)-benzyladenosine | N(6)-benzyladenosine: RN given refers to parent cpd | ||
6-(4-nitrobenzylthio)guanosine | 6-(4-nitrobenzylthio)guanosine: inhibitor of nucleoside transport | ||
5-iodotubercidin | 7-iodotubercidin: inhibits Toxoplasma gondii adenosine kinase | organoiodine compound | |
n(6)-phenyladenosine | purine nucleoside | ||
tecadenoson | tecadenoson: an A1 adenosine receptor agonist | ||
2-hydroxy-5-nitrobenzylthioguanosine | |||
n(6)-cyclopentyladenosine | |||
7,8,3'-trihydroxyflavone | 7,8,3'-trihydroxyflavone: a potent small molecule TrkB receptor agonist that protects spiral ganglion neurons from degeneration both in vitro and in vivo | ||
trilobatin | trilobatin : An aryl beta-D-glucoside that is phloretin attached to a beta-D-glucopyranosyl residue at position 4' via a glycosidic linkage. It is isolated from the leaves of the Chinese sweet tea Lithocarpus polystachyus and exhibits significant anti-hyperglycemic, anti-oxidative and anti-inflammatory properties. trilobatin: anti-inflammatory from Lithocarpus polystachyus leaves; structure in first source | aryl beta-D-glucoside; dihydrochalcones; monosaccharide derivative | anti-inflammatory agent; antioxidant; plant metabolite; sweetening agent |
6-benzylthioinosine | 6-benzylthioinosine: a subversive substrate of T gondii adenosine kinase; structure in first source |